Man vill förkorta betongs bindetid dvs. den tid då betongytan kan behandlas så att betongytan blir slät efter gjutning. Det är en stor utmaning för företag som tillverkar fabriksbetong vintertid, eftersom bindetiden förlängs ju kallare klimatet är. Syftet med denna labboration var att visa hur Kalciumnitrart fungerar som bindetidsaccelerator i betong, och om Kalciumnitrart påverkar betongens fysikaliska egenskaper.  Följande faktorer har studerats för att se hur dessa faktorer påverkar betongens bindetid i kombination med användning av Kalciumnitrat. Betongens utgångstemperartur Typ av flyttillsatsmedel i betongen Betongens utgångskonsistens Betongens lagringsklimat Även hitta rätt dosering för att denna produkt ska vara lönsamt att användas i praktiken. Alla underökningar har utförts hos Sika AB laboratorium. All data har noggrant undersökts och använts i Excel program för framtagning av tabeller och diagram. Resultaten/slutsats i underökningarna visade följande. Bindetiden kan förkortas med Kalciumnitrat utan att behöva riskera betongens fysikaliska egenskaper. Enligt bindetidsdiagram noterades att 2,0 % och 2,5 % doseringarna gav bästa resultat gällande bindetid dvs. de gav kortast bindetid. Observera att +5 graders lagringsklimat gav ologiska resultat dvs. referensbetongen utan acceleratorn gav kortast bindetid. Tryckhållfastheten påverkas inte av acceleratorn dvs. man kan använda denna produkt utan att riskera betongens bärförmåga. Resultaten visade att betongens utgångskonsistens har stor betydelse för bindetiden, ju högre konsistens värde desto längre bindetid. Även betongens utgångstemperatur har påverkan på bindetiden, ju högre betongtemperatur desto kortare bindetid. / You want to reduce the concrete’s initial setting i.e.  the time the concrete surface can be treated so that surface gets plane after molding. It’s a big challenge for the companies that produce mill concrete in winter. Since the colder the climate gets the binding process will be extended. The purpose of this lab was to show how Calcium Nitrate functions as bonding time accelerator in concrete and if Calcium Nitrate affects the physical features of the concrete. The following elements have been studied to see how these elements affect the initial setting of the concrete in combination with the use of Calcium Nitrate. The initial temperature of the concrete The type of super plasticizer in the concrete The initial consistency Concrete storage climate Even finding the right dose so that this product will be profitable to use in the practice. All investigations have been made at Sika AB laboratory. All the data have been investigated and used in excel program for the product of chart and diagram. The results of the investigations showed the following:   Bond time can be reduced with Calcium Nitrate without needing to risk the physical features of the concrete.  According to bonding time diagram it was noted that 2.0 % and 2.5% doses gave the best result valid the initial setting i.e. that gave the shortest time of initial setting, Observe that +5 degrees storage climate gave illogical results i.e. reference concrete without the accelerator gave the shortest initial setting. Compressive strength does not get affected by the accelerator i.e. you can use this product without risking the concretes carrying capacity.  The results showed that the concrete initial consistency has a big importance to bond time, the higher consistency value the longer time of initial setting. Even concrete initial temperature has influence on the bond time, the higher concrete temperature, the shorter time of initial setting.

Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions with other drugs and a variety of factors that influence the dosing of warfarin. Objective: The general objective of this study was to investigate the prevalence of drugs prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin. Methods: This was a cross-sectional, observational or qualitative study that was conducted on medicine claims data of a pharmaceutical benefit management company for patients receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31 December 2010. Drug products that were co-prescribed with warfarin were also identified from the medicine claims database. The total number of prescriptions for all drug products during the study period were analysed and compared to the warfarin dataset. This was done by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of prescriptions and medicine items claimed from the database during the study period were respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed drugs were identified and classified according to a clinically significant rating. The clinically significance ratings of potential DDls are described in three degrees of severity, identified as major, moderate and minor (Tatro, 2011 :xiv). Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of total number of medicine items. The total number of patients who claimed warfarin prescriptions through the database represented 0.9% (n=68 575) of the total number of patients who claimed prescriptions in the total database (2005-2010). General practitioners prescribed the highest frequency of warfarin medicine items, representing 58.3% (n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59 years and older). The distribution between females and males regarding warfarin prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items. Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDD between general practitioners and paediatric cardiologists. The average PDD of warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41 mg) was almost equal. The age group who was prescribed the highest average PDD was age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group 4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDDs of warfarin medicine items between these two age groups. The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2 (n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with warfarin in the six year study period. The five drugs that was co-prescribed with warfarin most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone (n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five drugs have a SR of 1. Conclusions: This study showed that the top five drugs most frequently prescribed with warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can potentially interact with warfarin. The potential interactions of these drugs are rated with a significance rating of 1. This concludes that drugs that can potentially cause life threatening effects and permanent damage are commonly co-prescribed with warfarin. Clinical data concerning the INR or PT must be obtained in order to evaluate whether or not warfarin therapy is changed when a potentially interacting drug is co-prescribed. The age of the patients as well as the duration of warfarin treatment should also be obtained in order to assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013

Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions with other drugs and a variety of factors that influence the dosing of warfarin. Objective: The general objective of this study was to investigate the prevalence of drugs prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin. Methods: This was a cross-sectional, observational or qualitative study that was conducted on medicine claims data of a pharmaceutical benefit management company for patients receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31 December 2010. Drug products that were co-prescribed with warfarin were also identified from the medicine claims database. The total number of prescriptions for all drug products during the study period were analysed and compared to the warfarin dataset. This was done by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of prescriptions and medicine items claimed from the database during the study period were respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed drugs were identified and classified according to a clinically significant rating. The clinically significance ratings of potential DDls are described in three degrees of severity, identified as major, moderate and minor (Tatro, 2011 :xiv). Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of total number of medicine items. The total number of patients who claimed warfarin prescriptions through the database represented 0.9% (n=68 575) of the total number of patients who claimed prescriptions in the total database (2005-2010). General practitioners prescribed the highest frequency of warfarin medicine items, representing 58.3% (n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59 years and older). The distribution between females and males regarding warfarin prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items. Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDD between general practitioners and paediatric cardiologists. The average PDD of warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41 mg) was almost equal. The age group who was prescribed the highest average PDD was age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group 4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDDs of warfarin medicine items between these two age groups. The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2 (n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with warfarin in the six year study period. The five drugs that was co-prescribed with warfarin most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone (n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five drugs have a SR of 1. Conclusions: This study showed that the top five drugs most frequently prescribed with warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can potentially interact with warfarin. The potential interactions of these drugs are rated with a significance rating of 1. This concludes that drugs that can potentially cause life threatening effects and permanent damage are commonly co-prescribed with warfarin. Clinical data concerning the INR or PT must be obtained in order to evaluate whether or not warfarin therapy is changed when a potentially interacting drug is co-prescribed. The age of the patients as well as the duration of warfarin treatment should also be obtained in order to assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013

Introduktion  Fallolyckor är den vanligaste typen av olycka hos äldre personer och det finns behov av nya fallpreventiva åtgärder där fysisk träning med mobilapplikation är en möjlighet. Syftet med studien var att undersöka om träningsmängden påverkar effekten av ett års fallpreventiv träning med mobilapplikation för äldre personer i ordinärt boende mätt i funktionell benstyrka, upplevd balans och benstyrka samt fallrädsla och hälsorelaterad livskvalité hos äldre personer.  Metod  Deltagarna medverkade i ett större projekt där de under ett år erbjudits fallpreventiv träning med en mobilapplikation. Innan studiens start samt efter 12 månader besvarades en enkät som behandlade bland annat ett 30 sekunders uppresningstest för funktionell benstyrka, upplevd balans, upplevd benstyrka, fallrädsla och hälsorelaterad livskvalité. Vid 12 månader skattade deltagarna även sin genomsnittliga träningsmängd under de senaste tre månaderna. Deltagarna delades in i grupper efter träningsmängd; ingen träning (n=13), <30 minuter (n=31), 30-59 minuter (n=13), ≥60 minuter (n=25). Effekten av träningen jämfördes mellan grupperna med hjälp av Kruskal–Wallis one-way analysis of variance. Resultat 82 deltagare inkluderades i denna studie, de hade en medelålder på 76 år, varav 72% var kvinnor. Gruppen som tränat ≥60 minuter hade signifikant förbättrad funktionell benstyrka samt upplevd benstyrka i dagsläget i jämförelse med hur den var för ett år sedan vid jämförelse med gruppen som tränat <30 minuter. De som tränat ≥60 minuter visade även en signifikant förbättring i upplevd balans i dagsläget i jämförelse med ett år sedan gentemot gruppen som inte tränat alls samt gruppen som tränat <30. Inga signifikanta gruppskillnader sågs i fallrädsla eller hälsorelaterad livskvalité. Konklusion Fallpreventiv träning som utförs ≥60 minuter i veckan ger signifikanta förbättringar i jämförelse med mindre träningsmängd gällande funktionell benstyrka samt upplevd balans och benstyrka i jämförelse med för ett år sedan.